HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer

Files in This Item:
Br J Cancer_109(12)_2980-2986.pdf413.41 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/56350

Title: Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer
Authors: Homma, Akihiro Browse this author →KAKEN DB
Sakashita, Tomohiro Browse this author
Yoshida, Daisuke Browse this author
Onimaru, Rikiya Browse this author →KAKEN DB
Tsuchiya, Kazuhiko Browse this author
Suzuki, Fumiyuki Browse this author
Yasuda, Koichi Browse this author
Hatakeyama, Hiromitsu Browse this author →KAKEN DB
Furusawa, Jun Browse this author
Mizumachi, Takatsugu Browse this author
Kano, Satoshi Browse this author
Inamura, Naoya Browse this author
Taki, Shigenari Browse this author
Shirato, Hiroki Browse this author →KAKEN DB
Fukuda, Satoshi Browse this author →KAKEN DB
Keywords: intra-arterial
cisplatin
maxillary sinus
chemotherapy
radiotherapy
Issue Date: 10-Dec-2013
Publisher: Nature publishing group
Journal Title: British journal of cancer
Volume: 109
Issue: 12
Start Page: 2980
End Page: 2986
Publisher DOI: 10.1038/bjc.2013.663
PMID: 24196792
Abstract: Background: The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS). Methods: Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100-120mgm(-2) per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis (n-5), brain necrosis (n-1), and ocular/ visual problems (n = 14) were observed as late adverse reactions. Conclusion: We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS.
Type: article (author version)
URI: http://hdl.handle.net/2115/56350
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 本間 明宏

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University